Identification of Predictors for Interstitial Lung Disease in Myositis Patients: A Systematic Review

Interstitial lung disease (ILD) is a well-recognized complication in the spectrum of diseases known as the idiopathic inflammatory myopathies (IIM). Individual studies of IIM-associated ILD have shown variation in the progression of the disease and, because of small sample sizes, prognostic factors seem to be difficult to identify. Prognostic factors are those characteristics or conditions that can be used to estimate or predict outcomes of disease. Because of the rarity of the disease, it is unlikely that large sample size studies will ever be performed, and a review and meta-analysis of previous studies provides a viable approach to improve the identification of prognostic factors. A meta-analysis is a statistical method for combining data from multiple studies to find unknown common results. This type of study is powerful because it aggregates data, leading to better estimates than can be obtained from any individual study. However, in this type of study, it is important to note that researcher bias in the criteria used to select studies, where to search for relevant studies, and other factors can significantly affect the results.

The purpose of this study was to identify relevant prognostic factors for IIM patients with ILD. The researchers searched databases for studies that addressed all causes of mortality in IIM-associated ILD to include in their review and meta-analysis.

From a total of 5892 articles reviewed, 32 were chosen for this analysis. The review included articles that appeared in the selected databases through August 9, 2018. Of the 32 articles selected for inclusion, 30 were conducted in Asia, which limits the ability to generalize the results: 22 in Japan, 6 in China, 2 in Korea. The remaining two were conducted in the US and Mexico. In total, 962 participants were included in the analysis. The criteria used for selection were that they had to examine ILD associated with polymyositis, dermatomyositis, clinically amyopathic dermatomyositis (CADM) and antisynthetase syndrome (ASS) in patients older than 16 years of age. From the 32 articles analyzed, 28 prognostic factors for all-cause mortality were identified. Potential prognostic factors were only included if they appeared in at least five of the studies. From the 28 prognostic factors identified, and using various types of analyses, six were found to be statistically significant:

Prognostic Factor Description Impact
Age The age of the patient The older the patient, the poorer the prognosis
Acute/subacute interstitial pneumonia (A/SIP) Abrupt or relatively abrupt onset of fever, cough, shortness of breath increasing in severity over 7-14 days If A/SIP is present, the poorer the prognosis
Percentage of predicted forced vital capacity Capacity of pulmonary function defined by the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible The lower the value, the poorer the prognosis
Anti-Jo-1 antibody A myositis-specific autoantibody most commonly found in patients with IIM If the antibody is present, the better the prognosis
Ground Glass Opacity/Attenuation (GGO/GGA) CT scan showing partial filling of spaces in the lungs by fluids and thickening of lung tissue The more significant the opacity, the poorer the prognosis
Extent of abnormality on high-resolution CT (HRCT) CT scan indicating lung damage The more abnormality, the poorer the prognosis

The authors note significant limitations in their study. Among other things, the quality of data was rated using a standardized evaluation system and was found to be either low or very low quality. And bias inherent in the individual studies included in this review are multiplied in meta-analysis. For example, many of the individual studies had very small sample sizes. The study also combined the four types of IIM and did not include any subgroup analysis. The heterogeneity of the four types may not be conducive to an all-inclusive analysis. Although these limitations are significant, the authors state that this was the first analysis of its kind and encourage further study on this important topic.

Kamiya H, Panlaqui OM, Izumi S, et al. Systematic review and meta-analysis of prognostic factors for idiopathic inflammatory myopathy-associated interstitial lung disease. BMJ Open 2018;8:e023998. doi:10.1136/bmjopen-2018-023998 –



Myositis Support and Understanding Association (MSU) is a patient-centered, all-volunteer 501(c)(3) nonprofit organization Empowering the Myositis Community. Founded by Myositis patients, for Myositis patients, MSU provides education, support, advocacy, access to research and clinical trial matching, and need-based financial assistance.

View more information: Myositis Support


Leave a reply

Your email address will not be published. Required fields are marked *


This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2024 Myositis Support and Understanding Association (MSU). All rights reserved. | View our Privacy Policy, Terms, and Non-Discrimination policy. MSU is a charitable organization with 501(c)(3) tax-exempt status. Federal ID #47-4570748.

Log in with your credentials


Forgot your details?

Register for Free Membership

Send this to a friend